• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Capricor Therapeutics Inc.

    10/17/23 4:05:13 PM ET
    $CAPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPR alert in real time by email
    SC 13G 1 tm2328179d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.     )*

     

    Capricor Therapeutics, Inc.
    (Name of Issuer)

     

    Common Stock
    (Title of Class of Securities)
     
    14070B309
    (CUSIP Number)

     

    October 3, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
         
      x Rule 13d-1(c)
         
      ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 14070B309 13G Page 1 of 5 Pages

    (l)

    Names of Reporting Persons.

     

    Nippon Shinyaku Co., Ltd.

    (2)

    Check the Appropriate Box if a Member of a Group

     

    (a) ¨

    (b) ¨

    (3)

    SEC Use Only

     

     

    (4)

    Citizenship or Place of Organization

     

    Japan

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    (5)

    Sole Voting Power

     

    2,145,922

    (6)

    Shared Voting Power

     

    0

    (7)

    Sole Dispositive Power

     

    2,145,922

    (8)

    Shared Dispositive Power

     

    0

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,145,922

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    6.97%*

    (12)

    Type of Reporting Person

     

    FI

     

    * Calculated based on 30,790,691 shares outstanding of the Issuer.

     

     

     

     

    Item l(a). Name of Issuer:

     

    Capricor Therapeutics, Inc.

     

    Item l(b). Address of Issuer’s Principal Executive Offices:

     

    840 Wilshire Blvd., 2nd Floor, Beverly Hills, California 90211

     

    Item 2(a). Name of Person Filing:

     

    Nippon Shinyaku Co., Ltd.

     

    Item 2(b). Principal Business Offices or, if None, Residence:

     

    14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku,

    Kyoto 601-8550, Japan

     

    Item 2(c). Citizenship:

     

    The Reporting Person is organized under the laws of Japan.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.001

     

    Item 2(e). CUSIP Number:

     

    14070B309

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) ¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

    (j) ¨ a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K),

     

     

     

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned:
       
      2,145,922
       
    (b) Percent of class:
       
      6.97%*
       
    (c) Number of shares as to which such person has:
       
    (i) Sole power to vote or to direct the vote:
       
      2,145,922
       
    (ii) Shared power to vote or to direct the vote:
       
      -
       
    (iii) Sole power to dispose or to direct the disposition of:
       
      2,145,922
       
    (iv) Shared power to dispose or to direct the disposition of:
       
      -

     

    5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    N/A

     

    8. Identification and Classification of Members of the Group.

     

    N/A

     

    9. Notice of Dissolution of Group.

     

    N/A

     

    10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

     

    * Calculated based on 30,790,691 shares outstanding of the Issuer.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Date: October 17, 2023
       
      By: /s/ Takanori Edamitsu
       
      Name and Title: Takanori Edamitsu, Director, Business Management & Sustainability

     

     

     

    Get the next $CAPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAPR

    DatePrice TargetRatingAnalyst
    5/20/2025$31.00Buy
    Roth Capital
    10/21/2024$35.00Overweight
    Piper Sandler
    5/17/2024$14.00Outperform
    Oppenheimer
    1/5/2024$8.00Overweight
    Cantor Fitzgerald
    10/26/2022$15.00Buy
    Ladenburg Thalmann
    1/31/2022$14.00 → $18.00Buy
    HC Wainwright & Co.
    10/11/2021$9.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CAPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Capricor Therapeutics with a new price target

      Roth Capital initiated coverage of Capricor Therapeutics with a rating of Buy and set a new price target of $31.00

      5/20/25 8:11:35 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Capricor Therapeutics with a new price target

      Piper Sandler initiated coverage of Capricor Therapeutics with a rating of Overweight and set a new price target of $35.00

      10/21/24 7:35:33 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Capricor Therapeutics with a new price target

      Oppenheimer initiated coverage of Capricor Therapeutics with a rating of Outperform and set a new price target of $14.00

      5/17/24 7:29:53 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    SEC Filings

    See more
    • SEC Form S-8 filed by Capricor Therapeutics Inc.

      S-8 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      6/16/25 5:00:51 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      5/27/25 9:15:17 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Capricor Therapeutics Inc.

      10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)

      5/14/25 4:30:49 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

      U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor's focus in neuromuscular diseasesCapricor remains on track for the August 31, 2025, PDUFA date for Deramiocel in Duchenne Muscular Dystrophy following successful FDA Pre-License Inspection SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Deramiocel, the company's lead cell therapy candidate, for the potential treat

      6/17/25 9:00:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

      U.S. FDA successfully completed Pre-License Inspection; Company expects facility will meet all requirements to support licensureAdvisory Committee meeting scheduled for July 30, 2025Mid-cycle meeting recently completed with no significant issues or major deficiencies; late-cycle meeting planned for mid-JulyBiologics License Application remains under priority review with PDUFA target action date of August 31, 2025 SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of the U.S. Food and Drug Admini

      6/11/25 9:25:00 AM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseasesThe National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor's StealthX™ exosome vaccine in the

      5/13/25 4:05:00 PM ET
      $CAPR
      Biotechnology: Pharmaceutical Preparations
      Health Care